Seeking Alpha

Celsion +8.4% on trial data presentation

  • "The impressive local response rate seen in these two studies was determined by lesion measurements and digital imaging data," says Dr. Hope Rugo. "Patients are pleased with the local control in the treated areas. I look forward to continuing my involvement in the Phase 2 portion of the DIGNITY study and its future application to clinical development of ThermoDox across different cancers."
  • Press release
  • Presentation
  • CLSN +8.4% premarket
From other sites
Comments (2)
  • Quoth the Raven
    , contributor
    Comments (2073) | Send Message
     
    It's the delivery, not the drug!
    13 Dec 2013, 09:03 AM Reply Like
  • ivansre@gmail.com
    , contributor
    Comments (3) | Send Message
     
    Hm 19.61% up at this moment. I hope that means something. I hope for my own good and the others...
    13 Dec 2013, 09:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector